« Return to News | Clinical Intelligence

Drug reduced number of MS lesions in phase II trial

Wednesday, April 18, 2012 12:37 PM

An investigational oral drug called ONO-4641 reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase II clinical trial supported by Ono Pharmaceutical.

In the phase II trial, 407 patients ages 18-55 with relapsing-remitting MS were randomly given placebo, 0.05mg, 0.10mg or 0.15mg of ONO-4641 once per day for 26 weeks. Study results showed that had 82%, 92% and 77% fewer Gd-enhancing brain lesions, respectively, compared to placebo.

Patients included in the study had two or more relapses in the two years prior to the study, one or more relapses within the year prior to the study or one or more new MS-related brain lesions, also known as Gd-enhancing lesions, which were detected on MRI within three months prior to the study. Brain scans were performed every four weeks from 10 to 26 weeks.

Adverse events appeared to be dose related and included cardiovascular events, such as a slower heartbeat, blood pressure changes and an AV block—the impairment of the conduction between the atria and ventricles of the heart. Other adverse events included liver enzyme elevations. In addition, grade four lymphopenia, which is an abnormally low level of lymphocytes in the blood, occurred in 4% of people receiving the 0.15mg dose of ONO-4641 and in 1% of those receiving the 0.10mg dose.

"In light of recent issues in the oral MS drug market, this is welcome news," said study author Timothy Vollmer, MD, of the University of Colorado in Denver and a fellow with the American Academy of Neurology.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.